Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU)

被引：2
|
作者：
Moulard, Odile [1 ]
Mehta, Jyotsna [2 ]
Olivares, Robert [1 ]
Iqbal, Usman [2 ]
Mesa, Ruben A. [3 ]
机构：
[1] Sanofi, Global Evidence & Value Dev, Chilly Mazarin, France
[2] Sanofi, Global Evidence & Value Dev, Cambridge, MA USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1744.1744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1744
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Progression to Myelofibrosis (MF) in Patients With Essential Thrombocythemia (ET): An Analysis From the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
    Yacoub, Abdularheem
    Lyons, Roger
    Braunstein, Evan
    Hamer-Maansson, J. E.
    Kalafut, Tricia
    Mesa, Reuben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S410 - S411
  • [42] TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    A Pardanani
    K-H Lim
    O Abdel-Wahab
    T L Lasho
    J Patel
    N Gangat
    C M Finke
    S Schwager
    A Mullally
    C-Y Li
    C A Hanson
    R Mesa
    O Bernard
    F Delhommeau
    W Vainchenker
    D G Gilliland
    R L Levine
    Leukemia, 2009, 23 : 905 - 911
  • [43] The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Thiele J.
    Kvasnicka H.M.
    Current Hematologic Malignancy Reports, 2009, 4 (1) : 33 - 40
  • [44] TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    Tefferi, A.
    Pardanani, A.
    Lim, K-H
    Abdel-Wahab, O.
    Lasho, T. L.
    Patel, J.
    Gangat, N.
    Finke, C. M.
    Schwager, S.
    Mullally, A.
    Li, C-Y
    Hanson, C. A.
    Mesa, R.
    Bernard, O.
    Delhommeau, F.
    Vainchenker, W.
    Gilliland, D. G.
    Levine, R. L.
    LEUKEMIA, 2009, 23 (05) : 905 - 911
  • [45] Fibrotic Transformation of Polycythemia Vera & Essential Thrombocythemia Is Biologically Indistinguishable from Primary Myelofibrosis
    Sangle, N. A.
    Teman, C.
    Perkins, S.
    Wilson, A.
    Bahler, D.
    Prchal, J.
    Salama, M. E.
    MODERN PATHOLOGY, 2011, 24 : 319A - 319A
  • [46] Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Nand, S
    Stock, W
    Godwin, J
    Fisher, SG
    AMERICAN JOURNAL OF HEMATOLOGY, 1996, 52 (01) : 42 - 46
  • [47] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis
    Mesal, Ruben A.
    Tefferi, Ayalew
    EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (03) : 471 - 479
  • [48] Fibrotic Transformation of Polycythemia Vera & Essential Thrombocythemia Is Biologically Indistinguishable from Primary Myelofibrosis
    Sangle, N. A.
    Teman, C.
    Perkins, S.
    Wilson, A.
    Bahler, D.
    Prchal, J.
    Salama, M. E.
    LABORATORY INVESTIGATION, 2011, 91 : 319A - 319A
  • [49] Factor V Leiden mutation is not a major cause of thrombotic tendency in essential thrombocythemia (ET) and polycythemia vera (PV).
    Gisslinger, H
    Rintelen, C
    Mannhalter, C
    Pabinger, I
    Geissler, K
    Knobl, P
    Eichinger, S
    Lechner, K
    BLOOD, 1995, 86 (10) : 3167 - 3167
  • [50] Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis
    Hasselbalch, Hans Carl
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (02) : 96 - 98
12345